688180 君实生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.362-14.720-19.689-27.454-27.404
总资产报酬率 ROA (%)0.163-7.556-11.579-19.107-20.243
投入资产回报率 ROIC (%)0.187-8.887-14.041-22.727-24.558

边际利润分析
销售毛利率 (%)83.18281.32878.92163.99665.304
营业利润率 (%)-1.121-40.004-68.717-163.551-183.414
息税前利润/营业总收入 (%)2.408-38.344-69.686-170.296-189.759
净利润/营业总收入 (%)-2.407-40.401-70.836-168.759-177.784

收益指标分析
经营活动净收益/利润总额(%)275.27592.44393.36992.68098.964
价值变动净收益/利润总额(%)-400.9214.8095.2473.0181.913
营业外收支净额/利润总额(%)43.0432.3271.3801.3750.421

偿债能力分析
流动比率 (X)1.8001.6041.7182.2854.086
速动比率 (X)1.6281.3981.4832.0643.746
资产负债率 (%)56.68551.08744.98135.46122.153
带息债务/全部投入资本 (%)46.31736.75830.45318.73910.697
股东权益/带息债务 (%)103.076152.932214.602411.315819.634
股东权益/负债合计 (%)73.83495.332120.838177.791340.888
利息保障倍数 (X)0.550-14.6779,401.88438.14234.070

营运能力分析
应收账款周转天数 (天)66.33573.21791.74586.422189.637
存货周转天数 (天)338.178446.650491.996378.341386.772